Tetraphase Pharmaceuticals Inc Revenue Growth Rates (TTPH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Tetraphase Pharmaceuticals Inc  (NASDAQ: TTPH)
 

TTPH's Revenue Growth by Quarter and Year

Tetraphase Pharmaceuticals Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TTPH Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 1.76
FY 1.76

TTPHs Annual Revenue
Tetraphase Pharmaceuticals Inc's Revenue in the fiscal year 2019 $ 7.38 millions
Tetraphase Pharmaceuticals Inc's Revenue in the fiscal year 2018 $ 18.90 millions
Tetraphase Pharmaceuticals Inc's Revenue in the fiscal year 2017 $ 9.67 millions
Tetraphase Pharmaceuticals Inc's Revenue in the fiscal year 2016 $ 5.15 millions
Tetraphase Pharmaceuticals Inc's Revenue in the fiscal year 2015 $ 11.69 millions




TTPH Revenue first quarter 2020 Y/Y Growth Comment
Tetraphase Pharmaceuticals Inc reported Revenue improvement of 38.19% year on year in the first quarter 2020, to $ 1.76 millions, this is lower than Tetraphase Pharmaceuticals Inc's recent average Revenue rise of 42.59%.

Looking into first quarter 2020 results within Major Pharmaceutical Preparations industry 68 other companies have achieved higher Revenue growth. While Tetraphase Pharmaceuticals Inc' s Revenue rise of 38.19% ranks overall at the positon no. 487 in the first quarter 2020.


TTPH Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - -60.51 % 69.17 % 132.11 %
3rd Quarter September - 190.43 % -71.74 % 378.82 %
2nd Quarter June - -90.76 % 628.3 % 28.23 %
1st Quarter March 38.19 % -32.8 % 26.85 % -23.98 %
FY   - -61.01 % 95.25 % -

Financial Statements
Tetraphase Pharmaceuticals Inc's first quarter 2020 Revenue $ 1.76 millions TTPH's Income Statement
Tetraphase Pharmaceuticals Inc's first quarter 2019 Revenue $ 1.27 millions Quarterly TTPH's Income Statement


TTPH Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - -49.4 % 272.17 % -37.84 %
3rd Quarter September - 212.15 % -90.07 % 155.97 %
2nd Quarter June - -15.75 % 512.7 % 6.71 %
1st Quarter March 3.85 % -70.33 % -25.3 % 36.7 %
FY (Year on Year)   - -61.01 % 95.25 % -


Back to TTPH Growth rate Comparisons >> Back to TTPH Growth rate Comparisons >>


Revenue first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #69
Healthcare Sector #148
Overall #487

Revenue Y/Y Growth Statistics
High Average Low
630.08 % 42.59 % -90.73 %
(Jun 30 2018)   (Jun 30 2019)
Revenue first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #69
Healthcare Sector #148
Overall #487
Revenue Y/Y Growth Statistics
High Average Low
630.08 % 42.59 % -90.73 %
(Jun 30 2018)   (Jun 30 2019)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Tetraphase Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
512.32 % 35.57 % -90.06 %
(Jun 30 2018)  


TTPH's I. Quarter Q/Q Revenue Comment
Tetraphase Pharmaceuticals Inc achieved in the I. Quarter 2020 below company average Revenue growth of 3.85% quarter on quarter, to $ 1.76 millions.

I. Quarter 2020 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -70.33% in the I. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 83 other companies have achieved higher Revenue quarter on quarter growth. While Tetraphase Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 930.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #84
Healthcare Sector #169
Overall #930
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #84
Healthcare Sector #169
Overall #930
Revenue Q/Q Growth Statistics
High Average Low
512.32 % 35.57 % -90.06 %
(Jun 30 2018)  


TTPH's I. Quarter Q/Q Revenue Comment
Tetraphase Pharmaceuticals Inc achieved in the I. Quarter 2020 below company average Revenue growth of 3.85% quarter on quarter, to $ 1.76 millions.

I. Quarter 2020 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -70.33% in the I. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 83 other companies have achieved higher Revenue quarter on quarter growth. While Tetraphase Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 930.


Tetraphase Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)		 12 Months Ending
(Mar 31 2019)
Cumulative Revenue 12 Months Ending $ 7.86 $ 7.38 $ 9.97 $ 7.78 $ 18.29
Y / Y Revenue Growth (TTM) -57.03 % -60.98 % -41.87 % -61.23 % 81.55 %
Year on Year Revenue Growth Overall Ranking # 257 # 3060 # 2265 # 3460 # 139
Seqeuential Revenue Change (TTM) 6.53 % -26.01 % 28.14 % -57.45 % -3.27 %
Seq. Revenue Growth (TTM) Overall Ranking # 2452 # 590 # 149 # 3703 # 2214


Cumulative Revenue growth Comment
Tetraphase Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2019. If the fiscal year would end in Mar 31 2020, Tetraphase Pharmaceuticals Inc's annual Revenue decline would be -57.03% year on year to $8 millions.

In the Healthcare sector 65 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 257, from total ranking in previous quarter at 3060.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 135
Healthcare Sector # 66
Overall # 257

Revenue TTM Y/Y Growth Statistics
High Average Low
300.42 %
 15.73 %
-61.23 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 135
Sector # 339
S&P 500 # 2452
Cumulative Revenue growth Comment
Tetraphase Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2019. If the fiscal year would end in Mar 31 2020, Tetraphase Pharmaceuticals Inc's annual Revenue drop would be -57.03% year on year to $8 millions.

In the Healthcare sector 65 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 257, from total ranking in previous quarter at 3060.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 135
Healthcare Sector # 66
Overall # 257

Revenue TTM Y/Y Growth Statistics
High Average Low
300.42 %
15.73 %
-61.23 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 135
Sector # 339
S&P 500 # 2452




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TTPH's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Mar 31 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2020
Zynex inc 65.59%$ 65.594 millions
Hookipa Pharma inc 65.37%$ 65.369 millions
Adaptive Biotechnologies Corporation65.09%$ 65.088 millions
Sangamo Therapeutics Inc 62.01%$ 62.012 millions
Scholar Rock Holding Corp61.94%$ 61.945 millions
Transmedics Group Inc 61.04%$ 61.035 millions
Adapthealth Corp 60.20%$ 60.202 millions
Lifemd Inc 59.50%$ 59.497 millions
Invitae Corporation58.43%$ 58.430 millions
Optinose Inc 57.77%$ 57.775 millions
Tivity Health Inc 57.71%$ 57.713 millions
Five Prime Therapeutics Inc 57.36%$ 57.359 millions
Acceleron Pharma inc56.26%$ 56.259 millions
Vir Biotechnology Inc 56.19%$ 56.187 millions
Vapotherm Inc 55.42%$ 55.419 millions
Arvinas Inc 55.35%$ 55.350 millions
Palvella Therapeutics Inc 55.19%$ 55.190 millions
Endonovo Therapeutics Inc 55.02%$ 55.021 millions
Immunogen inc 54.79%$ 54.788 millions
Strongbridge Biopharma plc53.67%$ 53.673 millions
Curis Inc 53.31%$ 53.311 millions
Aspira Women s Health inc 51.93%$ 51.930 millions
Interpace Biosciences Inc 50.73%$ 50.732 millions
Perspective Therapeutics Inc 49.69%$ 49.688 millions
Pulmonx Corporation49.15%$ 49.152 millions
Tandem Diabetes Care Inc 48.38%$ 48.384 millions
Silk Road Medical Inc 48.31%$ 48.308 millions
Caredx Inc 47.72%$ 47.718 millions
Alpha Pro Tech Ltd 47.55%$ 47.546 millions
Cyclo Therapeutics Inc 47.51%$ 47.507 millions


About Tetraphase Pharmaceuticals Inc Revenue Growth Rates (TTPH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.